国产血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班在急性心肌梗死支架置入术中的应用Application of Tirofiban in percutaneous coronary intervention for acute myocardial infarction patients
武维恒,祁春梅,刁军,冯建启,甘军民
摘要(Abstract)：
目的探讨国产血小板糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂替罗非班(欣维宁)在急性心肌梗死支架置入中的应用效果。方法64例急性心肌梗死患者按入院先后顺序分成两组冠状动脉内置入支架加用国产替罗非班组34例,冠状动脉内置入支架加用普通肝素组30例,观察两组患者用药后对冠状动脉再灌注的影响,并随访主要心脑血管事件和出血并发症。结果用国产替罗非班组达到TIMI2~3级血流的患者为97.1%(33/34),达到3级血流的患者为91.2%(31/34);用普通肝素组达到2~3级血流的患者为76.7%(23/30),达到3级血流的患者为70.0%(21/30),两组差异有统计学意义。国产替罗非班组的患者住院期间无主要心血管事件发生。结论特异性血小板GPⅡb/Ⅲa受体拮抗剂国产替罗非班对改善急性心肌梗死后血流再灌注及临床预后具有积极作用。
关键词(KeyWords)： 血小板糖蛋白GPⅡb/Ⅲa复合物;替罗非班;心肌梗死
基金项目(Foundation):
作者(Author): 武维恒,祁春梅,刁军,冯建启,甘军民
参考文献(References)：
- [1]The EPICinvestigarions:use of a monoclonal antibody directed against the platelet glucoproptein b/a receptor in high risk coronary angioplarty.NEngl J Men,1994,330:956.
- [2]O‘Neill WW,Serruys P,Knudtson M,et al.Longtermtreatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization.NEngl J Med,2000,342:1316.
- [3]Cannon CP,McCabe CH,Wilcox RG,et al.Oral glycoprote inⅡb/Ⅲa inhibition orbofibanin patients with unstable coronary syndromes(OPUS-TIMI16trial).Circulation,2000,102:149.
- [4]Kleiman NS,Califf RM.Results fromlate-breaking clinical trials sessions at ACCIS2000.J AmColl Cardiol,2000,36:310
- [5]Stone GW,Grines CL,Cox DA,et al.Comparison of angioplasty with stenting,with or without tirofiban,in acute myocardial infarction.NEngl J Med,2002,346:57-66.
- [6]Chan AW,Chen DP,Bhatt,DL,et al.long-term mortality benefit withthe combination of stents and tirofiban for cardio-genic shock complicatiy after a cute myocardial infardial infarction.Am J Cardiology,2002,89:132-136.